Avid Bioservices에 대한 매도 수량은 투자자에게 Avid Bioservices의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Avid Bioservices (NASDAQ:CDMO) 주식, 공매도 수량 보고

Avid Bioservices

Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

CDMO

UPWK

목요일(7일) 아침, 미국 주식 선물이 상승세를 보인 가운데, 오늘 투자자들의 관심을 끌 만한 종목은 다음과 같다. 

목요일 주목해야 할 주식: 허쉬, 업워크, 할리버튼, 애비드 바이오서비스 및 블록

Avid Bioservices Inc

WIIM

Dynatrace shares are trading lower. The company reported Q2 financial results.

XOMA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) reported quarterly losses of $(1.59) per share which missed the analyst consensus estimate of $(0.44) by 261.36 percent. The company reported quarterly sales of $9.197 million which beat the analyst consensus estimate of $6.493 million by 41.65 percent. This is a 1.01K percent increase over sales of $830.000 thousand the same period last year.

Earnings Beats

Earnings Misses

XOMA

XOMA Q3 2024 GAAP EPS $(1.59) Misses $(0.44) Estimate, Sales $9.197M Beat $6.493M Estimate

Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) reported quarterly losses of $(5.79) per share which beat the analyst consensus estimate of $(7.38) by 21.54 percent. The company reported $283.00 in sales this quarter. This is a 99.84 percent decrease over sales of $180.00 thousand the same period last year.

TRVN

Trevena Q3 2024 GAAP EPS $(5.79) Beats $(7.38) Estimate, Sales $283.00 Down From $180.00K YoY

The transaction is part of the objective UScellular announced on May 28, 2024, to opportunistically monetize the spectrum that was not included in the proposed sale to T-Mobile; and follows the transactions previously announced on October 18, 2024, to sell a portion of the retained spectrum licenses to Verizon and two other mobile network operators.
Following this transaction, as well as those previously announced, UScellular will have reached definitive agreements to monetize approximately 55%, measured on a MHz-Pops basis, of the spectrum holdings (excluding mmWave) that were excluded from the proposed sale to T-Mobile, for a total consideration of approximately $2.02 billion. &nbsp;

Asset Sales

United States Cellular Enters Agreement With AT&T To Sell Portion Of Its Retained Spectrum Licenses For Total Consideration Of $1.018B

CORRECTION: BCE Q3 2024 Adj. EPS CAD0.75 Misses CAD0.77 Estimate, Sales CAD5.971B Miss CAD6.032B Estimate

UBS analyst Steven Fisher initiates coverage on Martin Marietta Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLM#NYSE">MLM</a>) with a Buy rating and announces Price Target of $730.

Price Target

Initiation

Analyst Ratings

UBS Initiates Coverage On Martin Marietta Materials with Buy Rating, Announces Price Target of $730

Management

EHAB

Enhabit Home Health & Hospice Appoints Ryan Solomon As CFO, Effective Dec. 9

Needham analyst Bernie McTernan reiterates Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) with a Hold.

Reiteration

Needham Reiterates Hold on Zillow Gr

Dividends

Fidelity National Financial Increases Dividend From $0.48 To $0.50/Share

F&G Annuities & Life Increases Quarterly Dividend From $0.21 To $0.22/Share

Fiscal 2024 Outlook
Thilo Wrede, Vital Farms' Chief Financial Officer, commented: "With another solid performance in the third quarter, I am pleased to again update our guidance for 2024. Our new outlook reflects the strong performance of the business for the first nine months of this year and our good visibility for the fourth quarter of 2024. Our revised guidance is built around a favorable commodity outlook and strong consumer demand supported by our marketing reinvestment strategy. Vital Farms' long-term strategy is built to increase brand awareness, drive deeper loyalty with consumers, and grow our household penetration through focused energies on brand marketing and continuous retail expansion."
For the fiscal year 2024, management now expects:
<ul>
<li>Net revenue of at least $600 million, which represents at least 27% growth versus fiscal year 2023, compared to our previous expectation of at least $590 million, or 25% growth.</li>
<li>Adjusted EBITDA of at least $80 million, which represents at least 65% growth versus fiscal year 2023, compared to our previous expectation of at least $75 million, or 55% growth.</li>
<li>Capital expenditures for the full year in the range of $30 million to $40 million, which is reduced from our previous range of $35 million to $45 million due to updated timing on some key projects. We continue to evaluate our capital allocation priorities, and we will provide updates as necessary in future earnings reports. &nbsp;</li>
</ul>
Vital Farms' guidance includes the effect of lapping an extra shipping week in Q4 2023 and assumes that there are no significant disruptions to the supply chain or its customers or consumers, including any issues from adverse macroeconomic factors. Vital Farms cannot provide a reconciliation between its forecasted Adjusted EBITDA and net income and Adjusted EBITDA Margin and net income margin, their most directly comparable GAAP measures, without unreasonable effort due to the unavailability of reliable estimates for income taxes, among other items. These items are not within our control and may vary greatly between periods and could significantly impact future financial results.

Guidance

VITL

Vital Farms Sees FY24 Revenue Of At least $600M Vs $598.35M Est.

Z: 15% &#x7C; <a href="https://www.benzinga.com//node/41803768">Zillow Group shares are trading higher after the company reported better-than-expected Q3 financial results.</a>
&nbsp;
APP: 32% &#x7C; <a href="https://www.benzinga.com//node/41803196">Applovin shares are trading higher after the company reported better-than-expected Q3 financial results.</a>
&nbsp;
CYN: 63% &#x7C; <a href="https://www.benzinga.com//node/41803438">Cyngn Announced Progress Of Its Proprietary Computer Vision Technology For Industrial Autonomous Machines, Built On Nvidia Accelerated Computing</a>

Movers

Market-Moving News for November 7th

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Alector (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALEC#NASDAQ">ALEC</a>) with a Buy and maintains $35 price target.

ALEC

HC Wainwright & Co. Reiterates Buy on Alector, Maintains $35 Price Target

Clear Channel Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCO#NYSE">CCO</a>) announced its Q3 earnings on Thursday, October 31, 2024 at 06:00 AM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Clear Channel Outdoor missed estimated earnings by 0.0%, reporting an EPS of $-0.06 versus an estimate of $-0.06.
Revenue was up $32.20 million from the same period last year.
<h3>Overview of Past Earnings</h3>
During the previous quarter, the company beat on EPS by $0.01, leading to a 3.0% drop share price change the next day.
Here's a look at Clear Channel Outdoor's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.06</td>
<td>-0.05</td>
<td>-0.17</td>
<td>0.04</td>
<td>-0.08</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.06</td>
<td>-0.04</td>
<td>-0.17</td>
<td>0.05</td>
<td>-0.11</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>557.41M</td>
<td>562.37M</td>
<td>478.55M</td>
<td>610.14M</td>
<td>594.92M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>558.99M</td>
<td>558.54M</td>
<td>481.75M</td>
<td>632.11M</td>
<td>526.79M</td>
</tr>
</tbody>
</table>

<h3>Competitors that recently released earnings</h3>
When analyzing Clear Channel Outdoor's numbers, it's imperative to put them into context by comparing them to those of its competitors, like PubMatic, TechTarget, and National CineMedia.
<ul>
<li>PubMatic announced strong earnings on August 08, 2024, surpassing market expectations. Despite an estimated EPS of $-0.02, PubMatic's actual EPS was $0.17, reflecting a 950.0% increase.</li>
<li>TechTarget's earnings announcement on August 08, 2024 exceeded expectations, with an actual EPS of $0.42 compared to the market's projected EPS of $0.4, resulting in a 5.0% increase.</li>
<li>National CineMedia reported earnings on November 05, 2024 that fell short of expectations, with an actual EPS of $-0.04 compared to the market's estimate of $-0.03, resulting in a -33.33% decrease.</li>
</ul>
<h3>Insights into Competitors' Quarterly Earnings and Stock Performance</h3>
In this detailed analysis, insights are provided into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with their corresponding stock prices at the close of the announcement day and the open of the following trading day.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Date</th>
<th style="text-align: right;">EPS Expected</th>
<th style="text-align: right;">EPS Announced</th>
<th>EPS Change Percent</th>
<th>Stock Price At Close</th>
<th>Stock Price at Next Day Open</th>
<th>Price Change Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear Channel Outdoor</td>
<td>October 31, 2024</td>
<td style="text-align: right;">-0.06</td>
<td style="text-align: right;">-0.06</td>
<td>0.0%</td>
<td>$1.47</td>
<td>$1.48</td>
<td>0.68%</td>
</tr>
<tr>
<td>PubMatic</td>
<td>August 08, 2024</td>
<td style="text-align: right;">-0.02</td>
<td style="text-align: right;">0.17</td>
<td>950.0%</td>
<td>$19.6</td>
<td>$13.82</td>
<td>-29.49%</td>
</tr>
<tr>
<td>TechTarget</td>
<td>August 08, 2024</td>
<td style="text-align: right;">0.40</td>
<td style="text-align: right;">0.42</td>
<td>5.0%</td>
<td>$29.02</td>
<td>$28.38</td>
<td>-2.21%</td>
</tr>
<tr>
<td>National CineMedia</td>
<td>November 05, 2024</td>
<td style="text-align: right;">-0.03</td>
<td style="text-align: right;">-0.04</td>
<td>-33.33%</td>
<td>$7.3</td>
<td>$7.35</td>
<td>0.68%</td>
</tr>
</tbody>
</table>

<h3>Comparative Assessment: Estimated in Comparison with Actual Peer Revenues</h3>
The following table compares estimated and announced revenue figures for Clear Channel Outdoor's peers. This comparison provides insights into the revenue performance of these companies, offering valuable context to understand their financial standing within the industry.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Estimated Revenue</th>
<th>Announced Revenue</th>
<th>Revenue Surprise Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear Channel Outdoor</td>
<td>557.41M</td>
<td>558.99M</td>
<td>0.28%</td>
</tr>
<tr>
<td>PubMatic</td>
<td>70.12M</td>
<td>67.27M</td>
<td>-4.07%</td>
</tr>
<tr>
<td>TechTarget</td>
<td>58.08M</td>
<td>58.91M</td>
<td>1.44%</td>
</tr>
<tr>
<td>National CineMedia</td>
<td>58.02M</td>
<td>62.40M</td>
<td>7.55%</td>
</tr>
</tbody>
</table>

To track all earnings releases for Clear Channel Outdoor <a href="https://www.benzinga.com/quote/CCO/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Clear Channel Outdoor: Q3 Earnings Insights

Amylyx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.71) by 25.35 percent. The company reported $416.000 thousand in sales this quarter. This is a 99.59 percent decrease over sales of $102.693 million the same period last year.

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

Amylyx Pharma Q3 2024 Adj. EPS $(0.53) Beats $(0.71) Estimate, Sales $416.000K Down From $102.693M YoY

Jefferies analyst Julien Dumoulin-Smith initiates coverage on Edison Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>) with a Buy rating and announces Price Target of $93.

Jefferies Initiates Coverage On Edison Intl with Buy Rating, Announces Price Target of $93

CING

Cingulate Q3 Net Loss $3.2M

Biotech

Health Care

General

CALC

CalciMedica Has Appointed Stephen Bardin As Chief Financial Officer And The Planned Departure Of Daniel Geffken, Interim Chief Financial Officer Upon Filing The Company's Third Quarter Financial Statements

Reaffirms Full Year 2024 Outlook on Key Metrics
The Company is reaffirming its full year 2024 outlook on Key Metrics:
<ul>
<li>Net sales to decrease low to high teens in percentage terms, tracking toward the middle of the range.</li>
<li>Adjusted EBITDA(1) that is positive.</li>
<li>Free Cash Flow(1) that is positive. &nbsp;</li>
</ul>
Hydrofarm's 2024 outlook also reaffirms the following assumptions:
<ul>
<li>Reduced year-over-year Adjusted SG&amp;A(1) expense resulting primarily from (i) full year benefit of headcount reductions completed in 2023 and (ii) reductions in professional fees, facilities and insurance expenses.</li>
<li>Reduction in inventory and net working capital helping to generate positive Free Cash Flow(1) for the full year.</li>
</ul>
Hydrofarm's 2024 outlook also includes the following updated assumptions:
<ul>
<li>Adjusted Gross Profit Margin(1) that is flat to slightly down compared to the prior year. This is an update to the prior expectation of a year-over-year improvement.</li>
<li>Capital expenditures of $2.5 million to $3.5 million, compared to the prior expectation of $3.5 million to $4.5 million.</li>
</ul>
(1) Adjusted Gross Profit, Adjusted Gross Profit Margin, Adjusted SG&amp;A, Adjusted SG&amp;A as a percent of net sales, Adjusted EBITDA, and Free Cash Flow are non-GAAP measures. For reconciliations of GAAP to non-GAAP measures see the "Reconciliation of Non-GAAP Measures" accompanying the release.

HYFM

Hydrofarm Sees FY24 Net Sales To Decrease Low To High Teens In Percentage Terms, Tracking Toward The Middle Of The Range

Wedbush analyst Nick Setyan reiterates Dine Brands Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIN#NYSE">DIN</a>) with a Outperform and maintains $47 price target.

Wedbush Reiterates Outperform on Dine Brands Global, Maintains $47 Price Target

An announcement from Avid Bioservices ( ($CDMO) ) is now available. Avid Bioservices, Inc. has reported a strong start to fiscal 2025 with first-qu...

Avid Bioservices Reports Growth and Strong Pipeline

Avid Bioservices, Inc. (CDMO) Q1 2025 Earnings Call Transcript

In a report released yesterday, Sean Dodge from RBC Capital maintained a Buy rating on Avid Bioservices (CDMO – Research Report), with a price targ...

RBC Capital Sticks to Its Buy Rating for Avid Bioservices (CDMO)

Avid Bioservices stock rallies 18% after reporting increased backlog

Avidity Biosciences: Good Prospects, But We Are A Little Late

Avid Bioservices ( ($CDMO) ) has shared an update. At Avid Bioservices' 2024 Annual Meeting, stockholders approved significant amendments to the 20...

Avid Bioservices' Strategic Shareholder and Governance Updates

16:55 EST Avid Bioservices (CDMO) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breakin...

Avid Bioservices trading halted, news pending

18:35 EST Avid Bioservices (CDMO) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial n...

Avid Bioservices trading resumes

Avid Bioservices (CDMO), GHO Capital Partners LLP and Ampersand Capital Partners announced they have entered into a definitive merger agreement for...

GHO Capital / Ampersand Capital to acquire Avid Bioservices for $12.50 per share

RBC Capital downgraded Avid Bioservices (CDMO) to Sector Perform from Outperform with a price target of $12.50, up from $12, after the company anno...

Comments

Avid Bioservices

매도 수량

Avid Bioservices (NASDAQ:CDMO) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌